URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

George V. Migausky net worth and biography

George Migausky Biography and Net Worth

Director of Immunovant

George Migausky is a member of Immunovant’s board of directors. In 2017, Mr. Migausky served as interim Chief Financial Officer for Ocular Therapeutix, Inc. Prior to that, he served as Executive Vice President and Chief Financial Officer of Dyax Corp. a position he held from 2008 through the company’s acquisition by Shire for $6.4 billion in 2016. Before joining Dyax, Mr. Migausky served as Chief Financial Officer of Wellstat Management Company from 2007 to 2008; and Chief Financial Officer of IGEN International and BioVeris Corporation from 1986 through their acquisitions by F. Hoffman LaRoche in 2004 and 2007, respectively. Current directorships include Hyperion Catalysis International, a position he has held since 2008, and the Massachusetts Eye and Ear Institute, where he has served as a trustee since 2015. Mr. Migausky has previously served on the board of directors as Chair of the audit committee at Dimension Therapeutics, a position he held from 2015 until the company was acquired in 2017. Mr. Migausky received his BS from Boston College and his MBA from Babson College.

How do I contact George V. Migausky?: The corporate mailing address for Mr. Migausky and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on George V. Migausky's contact information.
Has George V. Migausky been buying or selling shares of Immunovant?: George V. Migausky has not been actively trading shares of Immunovant over the course of the past ninety days. Most recently, on Friday, August 20th, George V. Migausky bought 7,000 shares of Immunovant stock. The stock was acquired at an average cost of $7.65 per share, with a total value of $53,550.00. Learn More on George V. Migausky's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, insiders at the sold shares 38 times. They sold a total of 226,233 shares worth more than $6,598,313.84. The most recent insider tranaction occured on November, 20th when insider Mark S Levine sold 3,650 shares worth more than $92,892.50. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 11/20/2024.

George V. Migausky Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/20/2021	Buy	7,000	$7.65	$53,550.00

George V. Migausky Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $26.08

$25.44

$26.24

50 Day Range

MA: $28.40

$25.22

$31.42

2 Week Range

Now: $26.08

$24.61

$45.58

Volume

908,488 shs

Average Volume

1,068,167 shs

Market Capitalization

$3.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64